The peptide corresponding to amino acids 5355 - 5537 of the MLL2 protein (accession number NP_003473.3) was expressed in E. coli. The peptide contains the SET domain of MLL2 that is responsible for methyltransferase activity. Recombinant MLL2-SET contains an N-terminal GST tag with a molecular weight of 47.6 kDa.
Applikationshinweise
Recombinant MLL2-SET is suitable for use in the study of enzyme kinetics, inhibitor screening, and selectivity profiling.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Handhabung
Avoid repeated freeze/thaw cycles and keep on ice when not in storage.
Lagerung
-80 °C
Informationen zur Lagerung
Recombinant proteins in solution are temperature sensitive and must be stored at -80°C to prevent degradation.
Target
MLL2-SET
Hintergrund
Myeloid/lymphoid or mixed-lineage leukemia 2 (MLL2) is a Trithorax-group protein that function collectively to promote gene expression. MLL2 is a histone methyltransferase that methylates the Lysine 4 position of histone H3. In particular, the SET domain is a conserved C-terminal domain that characterizes proteins of the MLL (mixed-lineage leukemia) family. The SET domain is responsible for its histone methyltransferase activity which mediates chromatin modifications associated with epigenetic transcriptional activation. H3K4 methylation represents a specific epigenetic tag for transcriptional activation. MLL2 is part of a large protein complex called ASCOM, which has been shown to be a transcriptional regulator of the β-globin and estrogen receptor genes. Mutations in this gene have been shown to be a cause of Kabuki syndrome.